New drug treatment approved for high risk neuroblastoma

EUSA Pharma is pursuing registration and funding in Australia for Qarziba (also known as Dinutuximab-beta) an anti-GD2 monoclonal antibody for the treatment of high-risk neuroblastoma patients aged 12 months and over.